Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ956957,50,21
KB7507521,14
PKN64,3264,36-0,28
Msft271,2271,251,68
Nokia4,3914,3941,38
IBM135135,25-0,68
Mercedes-Benz Group AG72,9372,941,60
PFE44,0444,110,27
09.02.2023 13:23:48
Indexy online
AD Index online
select
AD Index online
 

  • 10.01.2023 10:07:12
Hikma Pharma (HIK.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
19,20 -1,52 -0,30 3 629
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.02.2023
Popis společnosti
Obecné informace
Název společnostiHikma Pharmaceuticals Plc
TickerHIK
Kmenové akcie:Ordinary Shares
RICHIK.L
ISINGB00B0LCW083
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.06.2022
Počet zaměstnanců k 31.12.2021 8 703
Akcie v oběhu k 31.01.2023 220 258 353
MěnaUSD
Kontaktní informace
Ulice1 New Burlington Place
MěstoLONDON
PSČW1S 2HR
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon442 073 992 760
Fax442073992761

Business Summary: Hikma Pharmaceuticals PLC is a pharmaceutical company. The Company’s principal activities are the development, manufacturing, marketing and selling of a range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments: Injectables, Generics and Branded. Injectables segment supply hospitals across its markets with generic injectables, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). Generics segment supply oral and other non-injectable generic and specialty branded products in the United States retail market. Branded segment supply branded generics and in-licensed patented products in MENA. It also markets its products in Canada and, which includes approximately 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Hikma Pharmaceuticals Plc revenues decreased less than 1% to $1.21B. Net income decreased 30% to $173M. Revenues reflect Injectable Pharmaceuticals segment increase of 9% to $538M, Branded Pharmaceuticals segment increase of 6% to $339M, Others segment increase of 20% to $6M, Middle East and North Africa segment increase of 5% to $414M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 09.02.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardSaid Darwazah6420.02.201801.07.2007
Executive Vice Chairman of the Board, President of MENAMazen Darwazah6308.09.2005
Chief Financial OfficerKhalid Nabilsi-01.01.2008
President, US Generics DivisionBrian Hoffman-01.01.2015
President - InjectablesRiad Mishlawi-01.01.2011
Executive Vice President - Corporate Development and M&ABassam Wael Rushdi Kanaan57
Executive Vice President - Organisational DevelopmentMajda Labadi-
Executive Vice President - Business OperationsHenriette Nielsen-01.01.2018
Executive Vice President - Strategic Planning and Global AffairsSusan Ringdal-
Chief Scientific OfficerShahin Fesharaki-01.01.2019